Phase 2 study of RK-023 patients with androgenetic alopecia (male pattern baldness) -A study for safety and preliminary estimation of hair re-growth in male subjects with androgenetic alopecia treated for 13 weeks with RK-023-

Trial Profile

Phase 2 study of RK-023 patients with androgenetic alopecia (male pattern baldness) -A study for safety and preliminary estimation of hair re-growth in male subjects with androgenetic alopecia treated for 13 weeks with RK-023-

Completed
Phase of Trial: Phase II

Latest Information Update: 31 May 2016

At a glance

  • Drugs RK 023 (Primary)
  • Indications Alopecia
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Sponsors R-Tech Ueno
  • Most Recent Events

    • 24 Jan 2011 Results were reported in a R-Tech Ueno media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top